Data from Gilead's latest drug shows promise
The company moves ahead on its leukemia treatment, after encouraging study results.
By Zacks Equity Research
Gilead Sciences, Inc. (GILD) recently presented encouraging data on its pipeline candidate, the leukemia drug idelalisib (formerly GS-1101), from a phase II study. That study is evaluating idelalisib, combined with Roche Holding AG’s (RHHBY) Rituxan/MabThera (rituximab), in treatment-naïve patients (ages 65 and older) suffering from chronic lymphocytic leukemia (CLL). The second most common leukemia form in the US, CCL refers to a slow-growing cancer. It stimulates the production of multiple mature white blood cells.
The results stated the regimen achieved an overall response rate of 97%, with estimated progression-free survival of 93% at 24 months. Encouraged by the results of the phase II study, Gilead intends to evaluate idelalisib for the indication in phase III studies.
Gilead plans to present detailed results from the phase II study at the annual meeting of the American Society of Clinical Oncology in Chicago at the end of the month.
The primary endpoint of the open-label, single-arm phase II study is the overall response rate. It refers to the proportion of patients achieving a complete or partial response with this regimen. As per the provisions of the trial, patients who complete 48 weeks of the combination therapy without the disease worsening could continue to receive idelalisib in an extension study.
Successful development and commercialization of idelalisib for the indication would boost Gilead’s top line -- since the CLL market offers significant commercial potential. Apart from CLL, idelalisib is also being evaluated in other oncology indications such as indolent non-hodgkin’s lymphoma and mantle cell lymphoma.
MSN Money on Twitter and Facebook
MORE ON MSN MONEY
Copyright © 2013 Microsoft. All rights reserved.
Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.
John Stumpf acknowledges that growth has been slow, but he says he's still optimistic.
VIDEO ON MSN MONEY
Top Stocks provides analysis about the most noteworthy stocks in the market each day, combining some of the best content from around the MSN Money site and the rest of the Web.
Contributors include professional investors and journalists affiliated with MSN Money.
Follow us on Twitter @topstocksmsn.